



CELLSPRAY® XP RECEIVES SWISS APPROVAL

Tuesday 30th March 2004, PERTH, AUSTRALIA: Clinical Cell Culture Ltd (C3, ASX: CCE) today announced that the Swiss Federal Office of Public Health has authorised the supply of CellSpray® XP into Switzerland.

Clinical Cell Culture Chief Executive Officer Troels Jordansen said the authorisation was an important step for C3 and a key milestone in the Company's plan for product commercialisation in Europe.

"The Swiss market is an advanced biological tissue market and our products are expected to be readily accepted by the Swiss Hospitals," Mr Jordansen said.

"The authorisation also represents the first European country outside the EU to authorise the use of CellSpray® XP."

The Swiss authorisation follows C3's earlier CellSpray® and CellSpray® XP European approvals announced on 9 January 2004 in Germany and Austria and on 13 February 2004 in The Netherlands and Denmark*. For more information on our CellSpray® products please refer to www.cellspray.info

C3 will sell its products into the above markets once the Belgium Health Authority issues a GMP certificate on behalf of C3 to Cambrex for the production of CellSpray® & CellSpray® XP. In early March 2004 C3 submitted a supplemental CellSpray® dossier. C3 has since been in contact with the Belgium Health Authority and it is expected that the Belgium Health Authority will provide C3 with an outcome of their review by late April 2004.

** For use in the Danish National Hospital in Copenhagen under trial in selected patients with Necrotising Fasciitis, a type of flesh-eating bacteria.*

ABOUT C3

Clinical Cell Culture (C3) is a publicly listed biomedical company that develops and distributes a number of tissue-engineered products for the treatment of wounds and other skin defects. Using proprietary tissue-culture/collection technology, C3 is able to provide innovative treatment solutions derived from the patients own skin, to enhance healing rates, reduce scar formation and reintroduce pigmentation into the skin.

The company's lead products are CellSpray®, a suspension containing cultured skin cells for use in the treatment of major burns and scars, and ReCell®, a device that enables the collection of healthy skin cells for immediate application on damaged skin such as small burns, areas of pigment loss and scars. C3's products have been used on more than 1,600 patients to date.

C3 is focused on further research and development. Pipeline products evolving from our R&D programme include EpiGrow®, an autologous skin derived fluid for the treatment of chronic wounds and SteriFast®, an end-point sterility diagnostic system that will allow testing of biological products within hours, compared to current technologies which can take several days.



C3 is currently internationalising its business by seeking regulatory approvals for its products throughout Asia-Pacific, Europe and USA. Regionalised commercial support staff will support the launch activities and will be supplemented through a global network of independent distributors/agents.

FOR FURTHER INFORMATION PLEASE CONTACT:

Troels Jordansen or Gabriel Chiappini
Clinical Cell Culture
Tel: +61 (0)8 9355 6288
Email: investor@clinicalcellculture.com

Paul Downie or Clair Stannard
Porter Novelli
Tel: +61 (0)8 9386 1233
Mob: +61 (0) 409 189 410